Anti-VEGF Innovations in Retinal Disease
Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.
A recent Ophthalmology Times Case-Based Roundtable discussion focused on the structural differences among newer second-generation anti-VEGF agents and their implications for clinical efficacy and treatment durability.
The discussion also highlighted real-world experiences and evidence regarding extended treatment intervals and sustained disease control with these newer therapies.
Stewart, MD, summarized the key takeaways from the discussion.
He presented a case of an 83-year-old woman with diabetic macular edema (DME) who underwent temporal grid laser photocoagulation for macular edema and received bevacizumab (Avastin; Genentech, Inc) intravitreal injections every 4 to 6 weeks.
Author's summary: Emerging anti-VEGF agents improve retinal disease treatment.
More News
- The Spectacle Podcast: From Empire State to Empty State
- Eala falls to Mboko to exit Hong Kong Open
- The Spectacle Podcast: Pierced, Lonely, and Lost – The New Symbols of America’s Decline
- NewJeans loses Ador court battle to leave agency
- Emmy-Winner Chronicles Yankees Icon Joe Torre’s MLB Legacy On Screen
- Trump Goes Full Dictator With Bonkers Threat to Use Air Force and Navy in U.S. Cities
- 10 High-Protein Fall Recipes
- A Difference of Opinion Editors: Interrogating the ethics of self-plagiarism in academia - Daily Bruin
- Pembroke Mafia Football League: Yet another exciting episode in the PMFL season
- Ahsoka Season 2 Gets Exciting Update From Rosario Dawson